Pharmaceutical

FDA grants fast track designation to AskBio’s AB-1005 for PD

Bayer and Asklepios BioPharmaceutical (AskBio) have announced FDA fast track designation for AB-1005, a gene therapy for PD.

Jul 14, 2024 - 04:00
FDA grants fast track designation to AskBio’s AB-1005 for PD
Bayer and Asklepios BioPharmaceutical (AskBio) have announced FDA fast track designation for AB-1005, a gene therapy for PD.
Read the original article

Tags:

Previous Article

Ipsen gains global rights to Foreseen Biotech’s FS001 ADC

Next Article

Pan Cancer T raises funds through seed extension round

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bayer’s stock drops to new 18-year low after asundexian trial termination

Bayer’s stock drops to new 18-year low after asundexian...

Nov 28, 2023

STAT+: More hospital pharmacists are rationing drugs due to increasing shortages

STAT+: More hospital pharmacists are rationing drugs du...

Aug 11, 2023

STAT+: Skin patch for toddlers with peanut allergy shows promising results in late-stage trial

STAT+: Skin patch for toddlers with peanut allergy show...

May 11, 2023